Major Birth Defects and Newer Antiepileptic Drugs
نویسندگان
چکیده
منابع مشابه
Newer-generation antiepileptic drugs and the risk of major birth defects.
CONTEXT Epilepsy during pregnancy is a therapeutic challenge. Since the 1990s, the number of licensed antiepileptic drugs has substantially increased, but safety data on first-trimester use of newer-generation antiepileptic drugs and birth defects are limited. OBJECTIVE To study the association between fetal exposure to newer-generation antiepileptic drugs during the first trimester of pregna...
متن کاملNewer antiepileptic drugs
Epilepsy is a very common neurological disorder with high prevalence and incidence. Several conventional antiepileptic drugs are being used for the treatment of various types of epilepsies. Over the last two decades, there has been a rapid expansion in the number and types of available antiepileptic drugs (AED). Newer AEDs are now available for the treatment of various forms of epilepsies. Lamo...
متن کاملAre newer antiepileptic drugs associated with improved safety in pregnancy compared to older antiepileptic drugs?
Commentary As a group, antiepileptic drugs (AEDs) are associated with an increased risk of major congenital malformations (MCMs) (1). Older AEDs are the best studied. Valproate (VPA) is consistently associated with an increased risk of MCMs including an increased risk of spina bifida (2). Phenobarbital (PB) exposure increases the risk of MCMs, including oral clefts (3). Although not consistent ...
متن کاملNeuroprotective effects of some newer and potential antiepileptic drugs
Experimental models of epilepsy or status epilepticus (SE) provide evidence that seizures result in diffuse brain damage. Other neurological conditions are also associated with neurodegeneration, for example, stroke, head injury and chronic neurodegenerative diseases. In this review, the neuroprotective effects of a number of newer or potential antiepileptic drugs (AEDs) are considered in gener...
متن کاملLacosamide, a newer antiepileptic.
Lacosamide (LCM) is a newer antiepileptic drug with a dual mode of action. It selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation, and modulates collapsing response mediator protein 2 (CRMP-2). It has a high oral bioavailability of approximately 100%. It has shown potent and broad neuroprotective effects in vitro and in vivo animal models ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pediatric Neurology Briefs
سال: 2011
ISSN: 2166-6482,1043-3155
DOI: 10.15844/pedneurbriefs-25-7-4